PathoVax, a Johns Hopkins–born startup developing a vaccine for human papillomavirus virus (HPV), raised $2.75 million in new funding, cofounder Joshua Wang said.

The equity funding round was led by United Heath Investments. The life science investment group is led by Dr. Alan Zhu, who is also director of the Baltimore-based Chinese Association for Medical Professionals, which counts 800 physicians as members and seeks to strengthen ties between medical communities in the U.S. and China. Private investors also participated.

The startup is developing RGVax, a vaccine that is designed to protect against all cancer-causing forms of HPV. Vaccines against the are already available, but only protect against some strains of the disease.

READ FULL ARTICLE HERE